1. Search Result
Search Result
Results for "

anticancer effects

" in MedChemExpress (MCE) Product Catalog:

430

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

6

Peptides

6

Inhibitory Antibodies

182

Natural
Products

21

Isotope-Labeled Compounds

2

Click Chemistry

12

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13670

    GI147211; OSI-211

    Topoisomerase Cancer
    Lurtotecan (GI147211; OSI-211), a semisynthetic Camptothecin analog, is a topoisomerase I inhibitor. Lurtotecan has anticancer effects .
    Lurtotecan
  • HY-145664

    Wee1 Cancer
    Myt1-IN-1 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132) .
    Myt1-IN-1
  • HY-N3369

    Longistyline C

    Others Cancer
    Longistylin C (Longistyline C) is a natural stilbene with anticancer effects .
    Longistylin C
  • HY-N10797

    Others Cancer
    (-)-Haplomyrfolin is a natural lignan with anticancer effects .
    (-)-Haplomyrfolin
  • HY-160219S

    Btk Cancer
    BTK-IN-33 is a Btk inhibitor with anticancer effects (WO2023174300A1; compound I) .
    BTK-IN-33
  • HY-N6579

    Others Cancer
    Arvenin I is a natural cucurbitacin glucoside with moderate anticancer effects .
    Arvenin I
  • HY-115709

    Others Cancer
    4,6-O-Benzylidene-D-glucose is a benzaldehyde derivative with anticancer effects .
    4,6-O-Benzylidene-D-glucose
  • HY-13670A

    GI147211 dihydrochloride; OSI-211 dihydrochloride

    Topoisomerase Cancer
    Lurtotecan dihydrochloride (GI147211), a semisynthetic Camptothecin analog, is a topoisomerase I inhibitor. Lurtotecan dihydrochloride has anticancer effects .
    Lurtotecan dihydrochloride
  • HY-162114

    PARP Cancer
    PARP1-IN-18 (compound 25) is a potent PARP1 inhibitor with an IC50 value of 2.7 nM. PARP1-IN-18 has anticancer effects .
    PARP1-IN-18
  • HY-145665

    Wee1 Cancer
    Myt1-IN-2 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28) .
    Myt1-IN-2
  • HY-150255

    Others Cancer
    IMP2-IN-3 is a potent IMP2 inhibitor. IMP2-IN-3 shows anticancer effects .
    IMP2-IN-3
  • HY-N3722

    Others Cancer
    O-Demethylmurrayanine is a natural phenol with anticancer effects. O-Demethylmurrayanine exhibits strong cytotoxicity against MCF-7 and SMMC-7721 with IC50 values in the range 4.42-7.59 μg/mL .
    O-Demethylmurrayanine
  • HY-123308

    Androgen Receptor Cancer
    VPC13163 is a potent androgen receptor (AR) BF3 inhibitor with an IC50 of 0.31 µM. VPC13163 has anticancer effects .
    VPC13163
  • HY-121362

    Bacterial Endogenous Metabolite Inflammation/Immunology
    Evernic Acid is a secondary metabolite generated by lichens, including Ramalina, Evernia, and Hypogymnia, and several studies have described its anticancer, antifungal, and antimicrobial effects. Neuroprotective and anti-inflammatory effects .
    Evernic Acid
  • HY-N3627

    NSC 680073

    Others Cancer
    Coronalolide methyl ester (NSC 680073) is a natural triterpene with anticancer effects. Coronalolide methyl ester shows moderately cytotoxic to KATO-3, SW-620, and Hep-G2 cells., with IC50 values of 8.64 µg/mL, 6.19 µg/mL, and 6.8 µg/mL, respectively .
    Coronalolide methyl este
  • HY-148974

    Polo-like Kinase (PLK) Cancer
    PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4) .
    PLK1-IN-5
  • HY-162245

    PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2 degrader-3 is a PROTAC degrader of the SWI/SNF ATPase subunits, SMARCA2. PROTAC SMARCA2 degrader-3 has anticancer effects (WO2023244764A1; Compound 153) .
    PROTAC SMARCA2 degrader-3
  • HY-158175

    EGFR Cancer
    EGFR T790M/L858R-IN-4 (Example 14) is a potent EGFR T790M/L858R inhibitor with anticancer effects .
    EGFR T790M/L858R-IN-4
  • HY-122782

    Lucialdehyde C

    Glucosidase Metabolic Disease Cancer
    Lucidal (Lucialdehyde C) is a natural lanostante-type triterpene aldehyde that shows inhibitory effects against α-glucosidase (Glucosidase) with an IC50 of 0.635 mM. Lucidal has anticancer and antidiabetic effects .
    Lucidal
  • HY-N7535

    Others Cancer
    Chlorovaltrate K is a chlorinated valepotriate with anticancer effects. Chlorovaltrate K shows moderate cytotoxicity against A549, PC-3M, HCT-8 and Bel 7402 cell lines with IC50 values of 2.32-8.26 μM .
    Chlorovaltrate K
  • HY-N3626

    Others Cancer
    Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
    Coronalolide
  • HY-157330

    P-glycoprotein Apoptosis Cancer
    P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .
    P-gp inhibitor 16
  • HY-P99538

    LFB-R603; TG-1101; TGTX-1101

    CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-157149

    MAP4K Cancer
    DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects .
    DS21150768
  • HY-160447

    Aurora Kinase FAK Cancer
    FAK/aurora kinase-IN-1 is a FAK and aurora kinase inhibitor with IC50 values of 6.61 nM and 0.91 nM, respectively. FAK/aurora kinase-IN-1 shows anticancer effects (WO2018019252A1; compound 11) .
    FAK/aurora kinase-IN-1
  • HY-162307

    PROTACs Keap1-Nrf2 Cancer
    Nrf2 degrader 1 (compound 1) is a PROTAC Nrf2 degrader with anticancer effects. Nrf2 degrader 1 inhibits cancer cells growth for A549 and LK-2 cells with IC50 values of 100 nM and 40 nM, respectively .
    Nrf2 degrader 1
  • HY-142922

    Bcr-Abl Cancer
    BCR-ABL-IN-4 is a BCR-ABL inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC50 values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11) .
    BCR-ABL-IN-4
  • HY-N10354

    Apoptosis Cancer
    27-Methyl withaferin A (comppund 26) is an apoptosis inducer with anticancer effects. 27-Methyl withaferin A shows antiproliferative effects against HeLa, A-549 and MCF-7 human tumor cell lines with IC50 values of 3.2 μM, 4.2 μM and 1.4 μM, respectively .
    27-Methyl withaferin A
  • HY-153276

    Androgen Receptor Cancer
    Androgen receptor-IN-5 is an androgen receptor inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .
    Androgen receptor-IN-5
  • HY-145817A
    lunresertib
    1 Publications Verification

    RP-6306

    Wee1 Cancer
    lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects .
    lunresertib
  • HY-P99473

    BI-505

    Integrin Cancer
    Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
    Bersanlimab
  • HY-113722

    Microtubule/Tubulin Cancer
    DAT1 is a potent antimitotic agent with anticancer effects. In HeLa cells, DAT1 blocks the spindle function by disturbing spindle microtubule and chromosome organization .
    DAT1
  • HY-153413

    Ras Cancer
    Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .
    Kras4B G12D-IN-1
  • HY-158407

    Apoptosis Cancer
    Anticancer agent 220 is a chromanone derivative with anticancer effects. Anticancer agent 220 shows highly potent activity in the colon cancer cell lines. Anticancer agent 220 induces apoptosis and cell cycle arrest in cells .
    Anticancer agent 220
  • HY-N7229

    DNA/RNA Synthesis Cancer
    Rabdosin B is an ent-kaurene diterpenoid with anticancer effects. Rabdosin B induces DNA damage in cells, and inhibits lettuce root hair development of seedlings .
    Rabdosin B
  • HY-141604

    CDX-011; CR011-vcMMAE

    Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
    Glembatumumab vedotin
  • HY-124808

    Ras Apoptosis Cancer
    IMM-01 is a mammalian Diaphanous (mDia)-related formins agonist that inhibits DID-DAD (diaphanous inhibitory domain-diaphanous autoregulatory domain) binding with an IC50 of 140 nM. IMM-01 acts by disrupting the autoinhibitory bond between the DID and DAD domain and thus activates formins. IMM-01 shows anticancer effects .
    IMM-01
  • HY-P99330

    Anti-Human VEGFA Recombinant Antibody; RO5520985

    VEGFR Tie Cancer
    Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
    Vanucizumab
  • HY-145303

    Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    DX2-201 is a potent and selective oxidative phosphorylation (OXPHOS) complex I inhibitor with an IC50 of 312 nM. DX2-201 has anticancer effects .
    DX2-201
  • HY-149602

    Glutaminase Reactive Oxygen Species Cancer
    Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC50 of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects .
    Glutaminase C-IN-2
  • HY-151915

    ATM/ATR mTOR Cancer
    ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .
    ATR-IN-20
  • HY-149099

    RET Cancer
    RET-IN-22 (compound 17b) is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively. RET-IN-22 shows highly selective profile to most kinases, especially to EGFR and VEGFR2. RET-IN-22 has anticancer effects .
    RET-IN-22
  • HY-15698A
    CRT0066101 dihydrochloride
    2 Publications Verification

    PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .
    CRT0066101 dihydrochloride
  • HY-15698
    CRT0066101
    2 Publications Verification

    PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .
    CRT0066101
  • HY-145432

    PI3K Cancer
    PI3K-IN-28 (Compound 6c) is a potent inhibitor of PI3K. PI3K-IN-28 displays the most potent activity with lower toxic effects on MCF-10a. PI3K-IN-28 displays half-maximal inhibitory concentration (IC50, μM) values of 5.8, 2.3, and 7.9. PI3K-IN-28 is the most potent one with a selectivity index (SI) of 39 and is considered as a latent lead for further optimization of anticancer agents .
    PI3K-IN-28
  • HY-N3831

    Bacterial Apoptosis Infection Inflammation/Immunology Cancer
    Epimedokoreanin B is a natural flavonoid with anticancer, anti-inflammatory and antibacterial effects. Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated apoptosis accompanied by autophagosome accumulation. Epimedokoreanin B is an anti-periodontitis agent that inhibits gingipains and Porphyromonas gingivalis growth and biofilm formation .
    Epimedokoreanin B
  • HY-12354
    SB-3CT
    15+ Cited Publications

    MMP Cancer
    SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity .
    SB-3CT
  • HY-123849

    PI3K mTOR Cancer
    SN32976 is a potent and selective class I PI3K and mTOR inhibitor with IC50s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .
    SN32976
  • HY-15698B

    PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC50 of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .
    CRT0066101 trihydrochloride
  • HY-164489

    EGFR Akt ERK Apoptosis Cancer
    KU004 is a potent dual EGFR/HER2 inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR and downstream Akt and Erk pathways and induces cell Apoptosis mainly via the extrinsic pathway. KU004 is a quinazoline derivative .
    KU004

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: